Stockreport

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio [Yahoo! Finance]

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoin [Read more]